Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Subsidiary, Insert Therapeutics, Awarded Patent for Cyclosert™ Camptothecin, the Company’s Lead Oncology Candidate

Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today the issuance of a patent covering its lead oncology product, IT-101. IT 101 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert™, and the potent anti-cancer compound camptothecin. The newly-issued United States Patent No. 7,270,808 entitled "Cyclodextrin-based polymers for therapeutic delivery" covers Cyclosert-linked prodrugs, including camptothecin and camptothecin derivatives.

Arrowhead Subsidiary, Insert Therapeutics, Awarded Patent for Cyclosert™ Camptothecin, the Company’s Lead Oncology Candidate

PASADENA, CA | Posted on September 24th, 2007

IT-101 is a nanoparticle therapeutic and has been in Phase I clinical trials since July 2006. In June 2007, interim Phase I data was published in the 2007 American Society for Clinical Oncology (ASCO) Proceedings (Abstract ID 32638), and reported stable disease in several patients who completed the six-cycle treatment regimen.

"The granting of this patent, that covers conjugates of the Cyclosert™ delivery polymers with camptothecin as well as a large number of other therapeutics, is an important milestone in our path to becoming a multi-product therapeutics company," said John Petrovich, President and Chief Executive Officer of Insert. "It enables us to continue our plan to build a portfolio of novel nanoparticle therapeutics that will benefit patients with cancer and a wide range of other diseases and conditions."

The full text of the Cyclosert-camptothecin patent may be found by conducting a patent number search utilizing the U.S. Patent Office's web site at .


About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ:ARWR) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has five subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, fullerene-based anti-oxidants, carbon-based electronics and compound semiconductor materials. For more information about Arrowhead and its subsidiary companies, please visit our website at .

About Insert Therapeutics

Insert Therapeutics, Inc. ( ), a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), is using its proprietary, nano-engineered, polymeric delivery system, CyclosertTM, to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. Insert’s affiliate company, Calando Pharmaceuticals, is using a related system for the systemic delivery of siRNA. The companies are pursuing this goal through internal research and development, and also through collaborations and partnerships with pharmaceutical and biotechnology companies.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our clinical studies, our ability to successfully develop and manufacture products, rapid technological change in our industry, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

For more information, please click here

Arrowhead Research
Virginia Dadey

Insert Therapeutics
John G. Petrovich

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Extracellular vesicles could be personalized drug delivery vehicles March 15th, 2018

Department of Materials Test Engineering (WPT) at TU Dortmund University uses Deben CT5000TEC stage to perform X-ray micro-tomography experiments for better understanding of damage progression in composite materials March 13th, 2018

Scientists Use Nanotechnology to Detect Molecular Biomarker for Osteoarthritis March 13th, 2018

Polymer nanoparticle shows ability to locate and treat breast tumors March 13th, 2018


Unexpected effect could lead to lower-power memory, computing devices March 17th, 2018

Imaging technique pulls plasmon data together: Rice University scientists' hyperspectral method analyzes many plasmonic nanoparticles in an instant March 16th, 2018

Plasmons triggered in nanotube quantum wells: Rice, Tokyo Metropolitan scientists create platform for unique near-infrared devices March 16th, 2018

Jim Barnhart Joins Nanometrics as Senior Vice President of Operations March 15th, 2018

Patents/IP/Tech Transfer/Licensing

NTU scientists create customizable, fabric-like power source for wearable electronics January 30th, 2018

IBM Breaks Records to Top U.S. Patent List for 25th Consecutive Year: IBM Inventors Receive Record 9,043 Patents in 2017 in Areas such as Artificial Intelligence, Cloud, Blockchain, Cybersecurity and Quantum Computing January 11th, 2018

A new product to help combat mouldy walls, thanks to technology developed at the ICN2 December 14th, 2017

Chinese market opens up for Carbodeon nanodiamonds: Carbodeon granted Chinese Patent for Nanodiamond-containing Thermoplastic Thermal Compounds December 4th, 2017

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project